tbuckley/cabot-search huggingface dataset:
A Diabetic Manual for the Mutual Use of Doctor and Patient.
Journal: JAMA (1920)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Quinacrine in possible or probable CJD
Authors: D. Braunholtz
Journal: BMJ (2002)

Concussion is a well-recognized clinical entity; however, its pathophysiologic basis remains a mystery. One unresolved issue is whether concussion is associated with lesser degrees of diffuse structural change seen in severe traumatic brain injury, or is the mechanism entirely caused by reversible functional changes. This issue is clouded not only by the lack of critical data, but also by confusion in terminology, even in contemporary literature. This confusion began in ancient times when no distinction was made between the transient effects of concussion and severe traumatic brain injury. The first clear separate recognition of concussion was made by the Persian physician, Rhazes, in the 10th century. Lanfrancus subsequently expanded this concept as brain “commotion” in the 13th century, although other Renaissance physicians continued to obscure this concept. By the 18th century, a variety of hypotheses for concussion had emerged. The 19th century discovery of petechial hemorrhagic lesions in severe traumatic brain injury led to these being posited as the basis of concussion, and a similar logic was used later to suggest diffuse axonal injury was responsible. The neuropathology and pathophysiology of concussion has important implications in neurology, sports medicine, medicolegal medicine, and in the understanding of consciousness. Fresh approaches to these questions are needed and modern research tools, including functional imaging and experimental studies of ion-channel function, could help elucidate this puzzle that has evolved over the past 3,000 years.
Electron Microscopic Survey of the Presence of Microvilli on Cultured Mammalian Cells&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: T. W. Cooper, Harold W. Fisher
Journal: JNCI Journal of the National Cancer Institute (1968)

Electron microscopic examination of the surface of a variety of cultured mammalian cells revealed that some cell strains have a density of microvilli greater than 10 per 100 μ2, whereas others have less than 2 per 100 μ2. The only correlation found between these two classes of cells is that those with the high density of microvilli were established in culture earlier than those almost devoid of microvilli.
Migraines may manifest as vertigo
Authors: Jean McCann
Journal: JAMA (1982)

In the differential diagnosis of dizziness as a primary symptom, consider migraine. So says Peter Behan, MB, ChB, consulting neurologist at the University of Glasgow, Scotland, who has seen 32 patients in three years whose primary symptom was recurrent vertigo of such severity as to send them to bed. The diagnosis was confirmed in these patients when all responded to antimigraine medication, Behan told an international migraine symposium, which was part of the World Neurology Congress held in Kyoto, Japan. The mean age of the patients was 30 years, with a range from 8 to 65 years. Thirty of the patients had at least a 50% reduction in their attacks when treated with 1 mg of pizotyline three times per day. In the other two patients, propranolol hydrochloride was effective. All patients were followed up for up to three years. Behan told<i>JAMA</i>MEDICAL NEWS that the new agent pizotyline
MULTICENTRIC RETICULOHISTIOCYTOSIS
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Medical schools in the United States
Journal: JAMA (1983)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intraosseous Hemorrhage of the Sacrum
Authors: ROSEANNE OLIVERIO, ELIZABETH OATES
Journal: Clinical Nuclear Medicine (1990)

Cold skeletal lesions on in-111 labeled leukocyte scans are relatively uncommon and may be seen in a variety of marrow-altering diseases, such as tumor, acute or chronic osteomyelitis, Paget's, and hemophiliac pseudotumor. A case of intraosseous hemorrhage, which produced a striking photopenic sacral lesion, is presented. Findings on bone scintigraphy, plain film, and CT scanning correlated well with this diagnosis.
TSNAdb v2.0: The Updated Version of Tumor-Specific Neoantigen Database
Authors: Jingcheng Wu, Wenfan Chen, Yuxuan Zhou, Ying Chi, Xiansheng Hua, Jian Wu, Xun Gu, Shuqing Chen, Zhan Zhou
Journal: Genomics Proteomics & Bioinformatics (2022)

Abstract In recent years, neoantigens have been recognized as ideal targets for tumor immunotherapy. With the development of neoantigen-based tumor immunotherapy, comprehensive neoantigen databases are urgently needed to meet the growing demand for clinical studies. We have built the tumor-specific neoantigen database (TSNAdb) previously, which has attracted much attention. In this study, we provide TSNAdb v2.0, an updated version of the TSNAdb. TSNAdb v2.0 offers several new features, including (1) adopting more stringent criteria for neoantigen identification, (2) providing predicted neoantigens derived from three types of somatic mutations, and (3) collecting experimentally validated neoantigens and dividing them according to the experimental level. TSNAdb v2.0 is freely available at https://pgx.zju.edu.cn/tsnadb/.
Clinical trials in systemic lupus erythematosus: the dilemma—Why have phase III trials failed to confirm the promising results of phase II trials?
Authors: Ana Lorenzo-Vizcaya, David Alan Isenberg
Journal: Annals of the Rheumatic Diseases (2022)

Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease of unknown aetiology, characterised by the production of auto-antibodies and formation of immune complexes against self-antigens and complement activation. This inflammatory response can lead to tissue infiltration and eventually, to organ damage. Patients with SLE invariably have periods of relapse and remission. Flares can occur even when the patient is on seemingly adequate treatment, which suggests that more effective therapies are necessary for the management of SLE. Thus, trials with many drugs against different targets, such as CD22, IL-12 and IL-23 or tyrosine kinases, have been carried out in recent years. A frustrating feature of some of the biologic drugs used to treat SLE has been the reporting of successful phase II trials followed by failures of the phase III trials. In this review, we will focus on phase II and III trials carried out with epratuzumab (anti CD22), baricitinib (Janus kinases inhibitor), rigerimod (P140 peptide) and ustekinumab (IL-12 and IL-23 inhibitor) and consider the reasons for their ultimate failure to ‘make the grade’. Likewise, we will try to explain the possible reasons that can influence why good results may be obtained in phase II trials and lead to undue optimism.
’We are not all in the same boat. We are in the same storm. Some are on super-yachts. Some have just the one oar.’ How COVID-19 exaggerated global inequities in professional sport
Authors: Nonhlanhla Sharon Mkumbuzi, Phathokuhle Cele Zondi, Oluwatoyosi B A Owoeye, Jane S Thornton, Joanne Kemp, Jonathan A Drezner
Journal: British Journal of Sports Medicine (2022)

The important mental, physical, social and fiscal role of organised, professional sport in our lives as athletes, athlete support personnel, consumers and various stakeholders was highlighted by the gaping hole its absence left after global COVID-19 lockdowns and restrictions brought professional sporting activities to a standstill.However, as seen in various industry sectors, clinical, and social settings, the burdens of the COVID-19 pandemic were borne unequally.While the clinical effects of the virus were similar worldwide, their implications were superseded by the different socioeconomic contexts in which they occurred.This editorial highlights how COVID-19 exacerbated global inequities in professional athletes' physical, mental and fiscal health outcomes and how those in low and middle-income countries (LMICs) were left further behind.
Antibiotics and probiotics impact gut antimicrobial resistance gene reservoir in COVID-19 patients
Authors: Qi Su, Qin Liu, Lin Zhang, Zhilu Xu, Chenyu Liu, Wenqi Lu, Jessica YL Ching, Amy Li, Joyce Wing Yan Mak, Grace Chung Yan Lui, Susanna So Shan Ng, Kai Ming Chow, David SC Hui, Paul KS Chan, Francis Ka Leung Chan, Siew C Ng
Journal: Gut Microbes (2022)

Dysbiosis of gut microbiota is well-described in patients with coronavirus 2019 (COVID-19), but the dynamics of antimicrobial resistance genes (ARGs) reservoir, known as resistome, is less known. Here, we performed longitudinal fecal metagenomic profiling of 142 patients with COVID-19, characterized the dynamics of resistome from diagnosis to 6 months after viral clearance, and reported the impact of antibiotics or probiotics on the ARGs reservoir. Antibiotic-naive patients with COVID-19 showed increased abundance and types, and higher prevalence of ARGs compared with non-COVID-19 controls at baseline. Expansion in resistome was mainly driven by tetracycline, vancomycin, and multidrug-resistant genes and persisted for at least 6 months after clearance of SARS-CoV-2. Patients with expanded resistome exhibited increased prevalence of Klebsiella sp. and post-acute COVID-19 syndrome. Antibiotic treatment resulted in further increased abundance of ARGs whilst oral probiotics (synbiotic formula, SIM01) significantly reduced the ARGs reservoir in the gut microbiota of COVID-19 patients during the acute infection and recovery phase. Collectively, these findings shed new insights on the dynamic of ARGs reservoir in COVID-19 patients and the potential role of microbiota-directed therapies in reducing the burden of accumulated ARGs.
Response to Open Peer Commentaries on “Privacy and Health Practices in the Digital Age”
Authors: Monique Pyrrho, Leonardo Cambraia, Viviane Ferreira de Vasconcelos
Journal: The American Journal of Bioethics (2022)

This article refers to:Privacy and Health Practices in the Digital AgeHealth Privacy, Racialization, and the Causal Potential of Legal RegulationsPrivacy and the Genetic CommunityProtecting Privacy While Optimizing the Use of (Health)Data: The Importance of Measures and SafeguardsHealthcare Organizations Should Be Accountable Stewards of Patient DataData, Privacy, and Agency: Beyond Transparency to EmpowermentProtecting Health Privacy through Reasonable InferencesRegulatory Angels and Technology Demons? Making Sense of Evolving Realities in Health Data Privacy for the Digital AgePrivacy, Health, and Race Equity in the Digital Age
An 85-Year-Old Woman With a History of Falls
Authors: Lewis A. Lipsitz
Journal: JAMA (1996)

<h3>Dr Delbanco:</h3> Mrs R is an 85-year-old widowed retired municipal worker who is the mother of 2 sons, one of whom is unmarried and lives with her in an urban community near Boston, Mass. Born in Italy, Mrs R came to the United States as a teenager and worked until retiring 10 years ago because of progressive arthritic pain and accompanying unsteadiness. She has no income other than Social Security, receives Medicare, and is eligible for lifesaving free medications at the Beth Israel Hospital, where she has been cared for by a general internist, Dr B, for more than 20 years. In recent years her medical problems have focused on difficulty walking and several falls and near falls, resulting in her being virtually homebound. She lives on the first floor of a house with a few steep steps outside the entrance, which limit her ability to move in and out
Characterization of a Herpes-Like Virus Recovered From Burkitt Lymphoma Cells (P3-J) and Propagated in Dog Thymus Cells. I. An Electron Microscope Study&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Journal: JNCI Journal of the National Cancer Institute (1968)

Electron microscopic studies of a herpes-like virus recovered from the P3-J line of Burkitt lymphoma cells superinfected with Moloney mouse sarcoma virus are described. The virus was initially isolated in newborn dog thymus cells in culture and demonstrated a productive type of infection as reported by Mitchell, Anderson, Bowles, and Hinz. To date all attempts to identify this agent antigenically have failed. Detailed ultrastructural studies of the developmental stages at different intervals after infection in dog thymus cells revealed the following: 1) The virus followed typical morphologic patterns associated with herpesviruses; 2) the particle size of both naked (immature) and membrane-associated virus was on the average within the size range of herpes simplex viruses; 3) electron-dense particles averaging 35mμ in diameter formed in the cytoplasm 4–8 hours after infection and appeared to be in a juxtanuclear membrane position; 4) similar dense particles appeared within the nucleus 6–8 hours after infection and concurrently with naked virus particle formation; 5) naked herpes-like virus particles were formed, approximately 8–12 hours after infection, in what appeared to be two ways: a) as a very dense, sharply limited viroplasmic-like substance within the nucleus and b) as single particles randomly distributed throughout a homogeneous nucleoplasm; 6) after naked virus production, the formation of membrane-associated virus was like that previously described for herpes simplex virus. The antigenic nature and oncogenic capacity of this agent are currently under investigation.
Preventive and Enhancing Effects of Retinoids on the Development of Naturally Occurring Tumors of Skin, Prostate Gland, and Endocrine Pancreas in Aged Male ACI/segHapBR Rats&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Masato Ohshima, Jerrold M. Ward
 4, Martin L. Wenk
Journal: JNCI Journal of the National Cancer Institute (1985)

The effects of dietary retinoids on the development of naturally occurring tumors in retired breeder male AChegHapBR rats were investigated. Groups of rats (21–25 mo of age, an age when early neoplasms first appear and tumor incidences are generally low) were fed diets containing 1 of 3 retinoids—all-trans-N-4-(4-hydroxyphenyl)retinamide (4-HPR), 783 mg/kg diet; all-trans-N-(4-pivaloyloxyphenyl)retinamide (4-PPR), 951 mg/kg; or all-trans-4-N-(2-hydroxyethyl)retinamide (2-HER), 687 mg/kg—or control diet for up to 54 weeks (average, 33 wk). Rats were maintained until less than 20% remained and the experiment was terminated. Contributing causes of death were determined, and a complete necropsy was performed for each rat. There was no difference between the retinoid-treated rats and control rats in the average age at death (30–31 mo) or in the average experimental survival time (29–35 wk), in the proportions of tumor-bearing rats (95.6–10O%), or in the average number of organs with tumor per rat (2.1–2.5). The incidences of pancreatic islet cell adenoma and skin tumors were significantly different between control and some retinoid-treated groups. 4-PPR and 2-HER significantly enhanced pancreatic islet cell adenoma yields (P<.025 and 0.05, respectively) whereas 4-HPR significantly inhibited epithelial and connective tissue skin tumor yields (P<.025). Incidences of skin and prostate tumors were lower than in controls, but not significantly, in rats receiving 4-PPR and 2-HER. Most of the islet cell adenomas were shown, by avidin-biotin-peroxidase complex immunocytochemistry, to be insulinomas. 4-HPR would seem to be the most effective retinoid in the group, inasmuch as it prevented skin tumor development, may have slightly decreased the incidence of prostate tumors, and did not enhance islet cell tumor incidence.
Do Toxic Tetrapeptides Play a Role in Fatal Viral Diseases?
Authors: Yechiel Becker
Journal: JAMA (1981)

CERTAIN viruses, such as the hemorrhagic fever viruses, arenaviruses, and togaviruses, are known to cause high mortality in human populations. Marburg and Ebola viruses cause death in most infected persons. During the smallpox era, there was a high fatality rate, and even today, more common viruses, such as influenza virus, can be fatal in young children and elderly people. Attempts to develop antiviral compounds have not as yet yielded a substance that can cure viral infections in the same way that antibiotics cure bacterial infections. In virus diseases with a high mortality, little can be done to save the patients in view of the high pathogenicity and morbidity of the viruses. Analysis of the pathological findings in patients who died after a virus infection indicated that organs were affected in which virus multiplication did not take place. Patients who died of smallpox in the first week of illness often showed
Calcium blockers: more than angina
Authors: Beverly Merz
Journal: JAMA (1982)

Calcium entry blockers, a class of drugs of which two—verapamil and nifedipine—have been approved by the Food and Drug Administration for the treatment of angina, have begun to show promise in certain other disorders involving smooth muscle as well. One such disorder is essential hypertension. Trials with both FDA-approved drugs have been in progress in Europe and Japan since the early 1970s and have yielded almost uniformly encouraging results. Among physicians in the United States who have administered the drugs to patients with hypertension on an individual basis, the feeling is one of cautious optimism. Other disorders are those that involve spasms in smooth muscle, such as asthma, achalasia, myometrial contractions, and migraine. Here, however, most investigators agree that it is much too early to issue a verdict. David Tinkleman, MD, assistant clinical professor of pediatrics at the Medical College of Georgia School of Medicine in Augusta, is conducting a
Medical News
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
'Bubble boy' reacts well to marrow transplant
Authors: Kathryn Simmons
Journal: JAMA (1983)

Twelve years of life in a plastic isolator bubble may be part of the past for David, the world's longest survivor of untreated severe combined immunodeficiency (SCID). On Oct 21, David received a bone marrow transplant from his 15-year-old sister at Texas Children's Hospital, Houston. The treatment— if successful—will free him to live in the open environment. It now appears that the risk period for the possible occurrence of acute graft v host disease (GVHD) has passed and, according to William T. Shearer, MD, Baylor College of Medicine, Houston, who heads the medical team caring for David, "his condition is excellent. We're very pleased with his medical progress and frame of mind. We're optimistic at this point." The signs of acute GVHD that the physicians were watching for in the first ten or so days were fever, rash, swollen glands, liver enlargement, and elevated liver enzymes. In an effort to